Compare ACFN & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACFN | GRML |
|---|---|---|
| Founded | 1986 | N/A |
| Country | United States | United States |
| Employees | 27 | 5 |
| Industry | Military/Government/Technical | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.8M | 41.9M |
| IPO Year | N/A | 2022 |
| Metric | ACFN | GRML |
|---|---|---|
| Price | $18.39 | $0.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.5K | ★ 3.0M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.42 | $0.27 |
| 52 Week High | $33.00 | $0.45 |
| Indicator | ACFN | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 49.43 | 52.14 |
| Support Level | $18.16 | $0.31 |
| Resistance Level | $19.87 | $0.43 |
| Average True Range (ATR) | 0.99 | 0.06 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 63.27 | 68.53 |
Acorn Energy Inc is a holding company that focuses on technology-driven solutions for energy infrastructure asset management. The company operates through two segments namely, the PG segment and the CP segment. PG segment provides wireless remote monitoring and control systems and services for critical assets as well as Internet of Things applications which account for the majority of the revenue. CP segment is engaged in providing remote monitoring of cathodic protection systems on gas pipelines for gas utilities and pipeline companies.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.